Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 15/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21809841 | 1.00 | SLC10A1 (0.44) | SLC10A1DRD4TSHRLMNAGAA | |
| SCHEMBL30095317 | 0.93 | SLC10A1 (0.44) | SLC10A1DRD4TSHRLMNAGAA | |
| SCHEMBL21809912 | 0.93 | SLC10A1 (0.44) | SLC10A1DRD4TSHRLMNAGAA | |
| SCHEMBL21809944 | 0.91 | SLC10A1 (0.46) | SLC10A1TSHRLMNAGAASIGMAR1 | |
| SCHEMBL30095060 | 0.91 | SLC10A1 (0.46) | SLC10A1TSHRLMNAGAASIGMAR1 | |
| SCHEMBL21809461 | 0.91 | SLC10A1 (0.42) | SLC10A1DRD4TSHRLMNAGAA | |
| SCHEMBL30095133 | 0.91 | SLC10A1 (0.42) | SLC10A1DRD4TSHRLMNAGAA | |
| SCHEMBL30095118 | 0.89 | SLC10A1 (0.47) | SLC10A1TSHRLMNASIGMAR1 | |
| SCHEMBL21809618 | 0.89 | SLC10A1 (0.47) | SLC10A1TSHRLMNASIGMAR1 | |
| SCHEMBL21809659 | 0.88 | SLC10A1 (0.46) | SLC10A1TSHRLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220298110-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2022-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | SLC10A1 225/4885DRD4 4842/4885TSHR 4281/4885 |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | SLC10A1 225/4885DRD4 4842/4885TSHR 4281/4885 |
| US-20220298110-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | SLC10A1 225/4885DRD4 4842/4885TSHR 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.